Evidence map›Paper›PMID 35568845›Full record

ArticleBMC cancer2022

RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma.

Cheng Lin, Meifang Li, Na Lin, Jingfeng Zong, Jianji Pan, Yunbin Ye

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. The Memory Gene,Biomolecules · 2025
    Article
  3. Article
  4. Article
  5. E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies.Journal of molecular medicine (Berlin, Germany) · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Cheng Lin *Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, China. happygo1988@sina.com.
Meifang Li *Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.
Na LinDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, China.
Jingfeng ZongDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, China.
Jianji PanDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, China.
Yunbin YeLaboratory of Immuno-Oncology, Fujian Cancer Hospital, Fuzhou, 350014, China. zjyunbin@fjmu.edu.cn.
Fujian Medical University · CNFujian Provincial Cancer Hospital · CN

Funding

Fujian Province Health Middle-aged and Young backbone personnel training Project 2020GGB010Joint Funds for the Innovation of Science and Technology 2019Y9037National Clinical Key Specialty Construction Program and Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy 2020Y2012Natural Science Foundation of Fujian Province 2020J05071the Startup Fund for scientific research, Fujian Medical University 2019QH1192
6 · The paper itself

Abstract

backgroundAccumulated evidence suggests that RING finger proteins (RNFs) are involved in the carcinogenesis of cancers. However, RNF38, a member of the RNF protein family, has not been studied in nasopharyngeal carcinoma (NPC).

methodsRNF38 expression was analyzed by RT-PCR, Western blotting and Immunohistochemistry. Biological functions of RNF38 were evaluated by cell growth, colony formation, apoptosis, migration and invasion assays in vitro. Xenograft growth and lung metastasis models were conducted to investigate the effect of RNF38 in vivo. Liquid chromatography coupled with tandem mass spectrometry, co-immunoprecipitation, and CHX assay were implemented to detect the interaction among RNF38 and ACTN4.

resultsRNF38 was significantly downregulated in NPC cells and tissues. Immunohistochemistry implied that loss of RNF38 was an independent prognostic factor for poor outcomes of NPC patients. Gain- and loss-of-function experiments showed that RNF38 inhibited proliferation and metastasis in NPC in vitro and in vivo. Upregulation of RNF38 promoted apoptosis of NPC cells to etoposide but not cisplatin. ACTN4 was upregulated in NPC and negatively correlated with RNF38. Mechanistic investigations suggested that RNF38 inactivates the NF-𝛋B and ERK1/2 signaling pathways by inducing ubiquitination and degradation of ACTN4. RNF38 suppress the development of NPC by interacting with ACTN4.

conclusionsRNF38 plays a potential cancer suppressor gene role in NPC tumorigenesis and is a prognostic biomarker in NPC.

Indexed as

Gene Expression Regulation, NeoplasticNasopharyngeal NeoplasmsActininCarcinogenesisCarrier ProteinsCell Line, TumorCell MovementCell ProliferationHumansNasopharyngeal CarcinomaUbiquitinationUbiquitin-Protein LigasesActininACTN4 protein, humanCarrier ProteinsRNF38 protein, humanUbiquitin-Protein LigasesACTN4GrowthMetastasisNasopharyngeal carcinomaRNF38Ubiquitination

Identifiers

PMID35568845
PMCPMC9107765
OpenAlexW4280489022

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.